Ownership Summary
According to SEC filings for the period ending December 2025, Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) is held by 10 institutional firms.
- The percentage of Coeptis Therapeutics Holdings owned by institutions changed from 5.5% in September 2025 to 17.0% in December 2025, marking a slight up trend.
- In percentage terms, this reflects as a holdings change of 301.32% quarter on quarter, and an increase of 25.00% year over year.
- The latest 13F cycle for Coeptis Therapeutics Holdings reveals that of 10 total investors, 7 funds grew their exposure, whereas 1 reduced theirs and 2 made no changes.
- The aggregate institutional position in Coeptis Therapeutics Holdings now stands at 445.81K shares as of December 2025, after investors increased their holdings (up by 334.72K shares quarter on quarter which is up 434.98K shares year over year).
- The top institutional stake in Coeptis Therapeutics Holdings as of December 31, 2025 belongs to VANGUARD GROUP INC, which owns 339.49K shares, or 12.97% of the company.
- Among the most significant buyers of Coeptis Therapeutics Holdings during December 2025 were VANGUARD GROUP INC (288.81K), MARSHALL WACE, LLP (18.19K), BlackRock, Inc. (13.57K), STATE STREET CORP (6.96K), GEODE CAPITAL MANAGEMENT, LLC (4.72K).
- Leading sellers of Coeptis Therapeutics Holdings stock in December 2025 included PNC FINANCIAL SERVICES GROUP, INC. (225).
- The top 10 institutional holders of Coeptis Therapeutics Holdings for the quarter ending December 2025 included VANGUARD GROUP INC (339.49K), GEODE CAPITAL MANAGEMENT, LLC (42.10K), STATE STREET CORP (26.83K), MARSHALL WACE, LLP (18.19K), BlackRock, Inc. (13.57K), Steward Partners Investment Advisory, LLC (5.00K), PNC FINANCIAL SERVICES GROUP, INC. (238), MORGAN STANLEY (200), UBS Group AG (193), BARCLAYS PLC (3).